Nexo Therapeutics launched with $60 million in Series A funding led by Versant Ventures and outlined a platform designed to discover covalent drugs against previously intractable cancer targets.
The announcement also detailed Nexo’s CODON chemistry engine and INFINI-T chemical biology capabilities, which are intended to broaden drug discovery beyond conventional cysteine-focused approaches and accelerate work against difficult cancer targets. The release introduced the company’s founding team and highlighted a parallel collaboration announcement with MD Anderson.
Nexo Therapeutics launched with $60 million in Series A financing led by Versant Ventures, with participation from New Enterprise Associates and Cormorant Asset Management. The company said the funding will support its discovery platform for novel oncology therapies built around covalent ligand discovery and chemical biology.